Author: Emma Yasinski

Emma Yasinski

I am a freelance science and medical journalist, fascinated by how the scientific process leads to incredible discoveries, but also can lead to publication bias leaning toward positive findings and minimizing negatives. With a bachelor’s degree in neuroscience from Lafayette College and a Master’s in Science and Medical Journalism from Boston University, I’ve written about clinical trial transparency, organ donation, and basic molecular biology for publications like The Scientist, The Atlantic, Undark.org, Kaiser Health News, and more. At MedShadow, I research and write about the sometimes unexpected ways that medicines can affect us, and what we can do if and when it does.

A new chemotherapy drug promises to treat some patients with pediatric acute lymphoblastic leukemia (ALL) who have been unable to take the other two other chemo medicines because one can cause allergic reactions and the other is frequently in short supply.  This summer, the Food and Drug Administration (FDA) fast-tracked the approval of Rylaze, a newer version of the chemo drug Erwinaze to treat ALL, made by Jazz Pharmaceuticals, which was previously distributed Erwinaze. The agency approved Rylaze based on an ongoing Phase 2/3 trial of about 102 patients, with an average age of 10.  The rare disease ALL affects…

Read More

May 26 Update: Only 62.6% of patients taking methotrexate, an immunosuppressant drug used in some cancer patients, mounted an effective antibody response to Pfizer’s vaccine, according to a study Stephanie, a Stage 4 endometrial cancer patient who has undergone both chemotherapy and immunotherapy since 2019, has been especially cautious throughout the pandemic. “We know how deadly this virus is, especially for older people and those who are immunocompromised,” like herself, she says. “And if not lethal, the complications for Covid-19 survivors are severe.”  The jury is still out on how exactly the COVID-19 vaccine affects cancer patients. Yet some studies point…

Read More